Teleflex Incorporated · NYSE:TFX
Teleflex — Investor Day (December 2012)
126 slides from Teleflex's investor day presentation, Dec 13, 2012
Slide 1: Teleflex Incorporated - 2012 Analyst Day
Teleflex Incorporated - 2012 Analyst Day December 13, 2012 Jake Elguicze Treasurer and Vice President Investor Relations 1 Exhibit 99.2
Slide 2: Agenda
Agenda Strategic Overview: Benson Smith - Chairman, President & Chief Executive Officer Strategic Business Unit and Regional Overviews: Senior Management Break Financial Overview: Thomas Powell - Senior Vice President & Chief Financial Officer Question & Answer Closing Comments Lunch 2
Slide 3: Forward-Looking Statements/Additional Notes
Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, new product and product line extension launches; facility rationalizations; long-term growth and profitability objectives over the next 5
Slide 4: Benson Smith, Chairman, President and CEO
Teleflex Incorporated - 2012 Analyst Day Benson Smith Chairman, President and Chief Executive Officer December 13, 2012 4
Slide 5: Agenda
5 Agenda Changing Medical Device Marketplace Pillars of Strategic Growth Plan Focus on Innovation Long-Term Goals and Objectives Rationalization vs. Investment Acquisition Approach Why Teleflex Will Win? 5
Slide 6: Changing Medical Device Marketplace
Changing Medical Device Marketplace Two competing forces are changing the medical device industry as we once knew it... Increased Utilization Cost Pressures Vs. It is becoming more complex for device companies to succeed 6 Innovation
Slide 7: Clinical complications across device categories
Vascular CRBSI Occlusion Thrombosis DVT Needle stick accuracy Catheter positioning Arterial cannulation Pneumo/Hemothorax Catheter migration Phlebitis Infiltration Stenosis Kinking Exit site hemostasis Malpositioning Recirculation rates Clearance rates Urology UTI Encrustation Strictures Lubricity A
Slide 8: Teleflex Today: Geographic revenue mix
Teleflex Today... Americas EMEA Asia OEM 526.685 377.513 123.205 104.55 Well positioned geographically Note: Amounts shown represent percentages of total revenues for the nine months ended September 30, 2012, per Form 10Q. 8
Slide 9: Teleflex Today: Diversified revenue by segment
Teleflex Today... Critical Care Surgical Care Cardiac Care OEM Other 754.4 214.8 57.7 104.6 0.5 Diversified...not dependent upon any one single product or procedure 9 Note: Amounts shown represent percentages of total revenues for the nine months ended September 30, 2012, per Form 10Q.
Slide 10: Pillars of our Strategic Growth Plan
Pillars of our Strategic Growth Plan Pricing - close the gap between ourselves and competitors Innovation - new product introductions and line extensions Rationalization - reduce facility footprint Investments - key geographic, capital and R&D initiatives Acquisitions - build the portfolio Service -
Slide 11: Long-term Goals and Objectives
Long-term Goals and Objectives Build upon a strong operating platform Generate above-market-average revenue growth and capture market share in key product areas Expand gross and operating margins 11
Slide 12: Focus on Innovation: New product revenue
Focus on Innovation Recent investments beginning to pay a dividend... Q3 2012 Sep-12 YTD Year-over-Year New Product Revenue Increases 5.5 14.4 Year-over-Year Increases in Revenues: New Products Source: 2012 Form 10Q filings. 12 $ in Millions
Slide 13: Focus on Innovation: Key New Product Launches
Focus on Innovation: Key New Product Launches 2012 Softech Plus Nasal Cannula Arrow FlexTip Plus Multi-Port Epidural Catheter ISO-Gard Circuit Technology Arrow FlexBlock Continuous Peripheral Nerve Block Catheter 4,5,6Fr IR PICC IR PICC w/ Chloragard AT 510(k) on PICC Pre-loaded PICC w/ ARROW VPS(tm
Slide 14: Focus on Innovation: Robust product pipeline in 2013
Focus on Innovation Robust product pipeline in 2013 Expectation that new product sales contribute ~ 1.0% to 1.5% of 2013 revenue growth Mix of newly introduced products expected to contribute positively to margins in 2013 and beyond 14
Slide 15: Rationalization vs. Investment
Rationalization vs. Investment A key to future gross and operating margin expansion is to reduce operational footprint, while balancing additional investments North American distribution center, and Mount Holly, N.J. manufacturing consolidation announcements in 2012 are the first steps Additional fo
Slide 16: Rationalization vs. Investment
Rationalization vs. Investment Limit the addition of commercial expenses to higher-growth geographies China Brazil Targeted information technology capital expenditure initiatives Reduce future headcount through common processes Manage additional expenses associated with internal and external researc
Slide 17: Acquisition Approach
Acquisition Approach Fits into our existing strategic business unit franchises and call points Product provides a superior clinical benefit to existing alternatives Provides a cost benefit to a hospital Strong IP and patent protection Difficult for competitors to follow 17
Slide 18: Service
Service We want to be the partner of choice for all customers Significant improvement made during last two years On-time deliveries to customers Reduction of backorders Well-positioned with all major Group Purchasing Organizations and Integrated Delivery Networks 18
Slide 19: Why Will Teleflex Win?
Why Will Teleflex Win? Opportunity to generate above-market revenue growth rates Not dependent upon any one product or geography Not overly impacted by elective procedure downturns Established, global distribution network Near-term pricing opportunities Mix of future new products Ability to improve
Slide 20: Thank you for your attention
Thank you for your attention 20
Slide 21: Paul Molloy, President - Vascular Division
Teleflex Incorporated - 2012 Analyst Day Paul Molloy President - Vascular Division December 13, 2012 21
Slide 22: Key Takeaways
22 Key Takeaways Market Overview Strategic Priorities Acquisition Update Research and Development Pipeline Summary 22
Slide 23: Market Overview
Market Overview 23
Slide 24: Global Vascular Access Position by Product Group
Global Vascular Access Position by Product Group Dollars in Millions Global Position by Product Group 2011 Market CAGR $165 ++% $502 >7% $55 5-7% $910 New segment $431 3-10% 3% 5% 0% 67% Market data and Arrow percentages based on management estimates. Actual amounts could differ. 24
Slide 25: Global CVC Market
Global CVC Market $CAGR 10+% 3% $431M $491M $526M $459M $564M Market data and Arrow percentages based on management estimates. Actual amounts could differ. 25
Slide 26: Global PICC Market
Global PICC Market CAGR 20%+ 4% $502M $561M $595M $530M $632M Market data and Arrow percentages based on management estimates. Actual amounts could differ. 26
Slide 27: Global Arterial Market
Global Arterial Market CAGR 8% 5% $55M $61M $65M $58M $69M Market data and Arrow percentages based on management estimates. Actual amounts could differ. 27
Slide 28: Strategic Priorities
Strategic Priorities Teleflex:
Slide 29: Strategic Priorities: ARROW Franchise
ARROW Franchise Life Cycle Management CVC product upgrades - move to Ergo-pack and custom kits Ergo-arterial product expansion Niche market entry product enhancements AGB+ registration overseas PICC Market Share Expansion Antimicrobial / Antithrombogenic label leverage in United States VasoNova navi
Slide 30: Strategic Priorities
Strategic Priorities International market expansion Global ARROW brand development leading to power-brand profitability Development of a consultative selling organization R&D Pipeline Semprus Sustain Next generation VPS system launch Preloaded VPS/PICC progressing to Antimicrobial / Antithrombogenic
Slide 31: Acquisition Update
Acquisition Update 31
Slide 32: ARROW VPS (VasoNova acquisition)
Adoption of ARROW VPS(tm) in U.S. market continues 53 accounts won since January 2012; > 50% from Bard with > 30% PICC pull-through CE Mark certification received on VasoNova VPS International product release in Q1 2013 ARROW VPS(tm) (VasoNova acquisition) 32
Slide 33: Semprus Biosciences (Sustain technology)
Semprus Sustain(tm) Polymer Protective Water Layer Medical Device Surface Proteins, RBCs & Bacteria Semprus Biosciences (Sustain(tm) technology) 33
Slide 34: Research and Development Pipeline
Research and Development Pipeline 34
Slide 35: 2012 - 2013 New Product & Line Extensions
2012 - 2013 New Product & Line Extensions 2012 4,5,6Fr IR PICC 2013 IR PICC with Chloragard AT 510(k) on PICC Pre-loaded PICC w/ ARROW VPS(tm) G4 ARROW VPS(tm) Peripheral IV - Endurance G2 ARROW VPS(tm) Sensor Nurse CVC - JACC G4 ARROW VPS(tm) w/ ultrasound 35
Slide 36: ARROW Endurance
Key New Product & Line Extension Launches ARROW Endurance(tm) PRODUCT DESCRIPTION Long in-dwell, advanced coatings, pressure injectable, peripheral vascular catheter & insertion system LAUNCH DATE Q4 2013 36
Slide 37: ARROW VPS Catheter Navigation System
Key New Product & Line Extension Launches ARROW VPS(tm) (Catheter Navigation System) Wireless tablet display and sleek keyboard-free hardware offering substantial new capabilities LAUNCH DATE Q2 2013 Q4 2013 with US & needle guidance 37 PRODUCT DESCRIPTION
Slide 38: ARROW JACC Nurse Insertion CVC System
Key New Product & Line Extension Launches ARROW JACC(tm) Nurse Insertion CVC System PRODUCT DESCRIPTION All new Nurse-edition pressure- injectable Ergo Pack with Peel-away ARROW sheath and advanced AM/AT coatings. LAUNCH DATE Q3 2013 38
Slide 39: Summary
Summary 39
Slide 40: Summary
Summary 40 Malposition Thrombosis Infection ZERO Complications Post-Insertion Complications Insertion Related Complications Top Down C-Suite, Risk Management, Value Analysis Bottom Up Clinicians, Infection Control, Purchasing Health-economics driven product development portfolio allowing premium pri
Slide 41: Thank you for your attention
Thank you for your attention 41
Slide 42: Jay White, Surgical Division
Teleflex Incorporated - 2012 Analyst Day Jay White Vice President & General Manager - Surgical Division December 13, 2012 42
Slide 43: Key Takeaways
43 Key Takeaways Market Overview Strategic Priorities Acquisition and New Product Development Update Summary 43
Slide 44: Market Overview
Market Overview 44
Slide 45: Global Surgical Market
Global Surgical Market Dollars in Millions $6.6B $6.0B $7.0B Market data and Teleflex percentages based on management estimates. Actual amounts could differ. Market CAGR $140 6.3% $396 5.2% $465 3.3% $1,021 3.8% $3,025 6.0% 67% 1% 2% 1% 1% 45
Slide 46: Strategic Priorities
Strategic Priorities 46
Slide 47: Strategic Priorities: Closure, Access, Manipulation
Closure Drive penetration and expand market opportunity for existing polymer platform Optimize pull thru with robotic procedures Successful development and execution of automatic ligation platform Access Successful global launch of Weck EFx - Endo Fascial Closure System Successful global launch of W
Slide 48: Strategic Priorities - Laparoscopic Cholecystectomy
Gain Access to the Abdominal Cavity Needles Weck Vista Ports Create Critical View Pilling atraumatic graspers & Maryland dissector Dissect Gallbladder from the Liver Bed Monopolar cautery / Energy Pilling scissors/ shears Remove Gallbladder Rusch Memo-bag Exclude Presence of Stones in the Common Bil
Slide 49: Acquisition and New Product Development Update
Acquisition and New Product Development Update 49
Slide 50: 2012 - 2013 New Products & Line Extensions
2012 - 2013 New Products & Line Extensions 2012 Pilling Containers 2013 Weck EFx Weck Vista Balloon Expansion Weck Vista Optical Trocar Weck Vista Reposable Obturator Weck Vista Robotic Trocar Next Generation Automatic Applier Microsurgery Launch Pilling Lap Instruments Weck AE5 50
Slide 51: Weck Hem-o-lok Auto-Endo5
Key New Product & Line Extension Launches Weck Hem-o-lok(tm) Auto-Endo(tm)5 PRODUCT DESCRIPTION Pre-loaded automatic polymer ligation system featuring: Distal locking polymer clip Medium/Large clip on 5mm platform Pre-loaded Automatic mechanism LAUNCH DATE General Surgery Focus - MARCH 2012 51
Slide 52: WECK EFx Endo Fascial Closure System
Key New Product & Line Extension Launches WECK EFx(tm) Endo Fascial Closure System PRODUCT DESCRIPTION Endo Fascial Closure System designed for: Reproducible, uniform closure across patient anatomy Minimized risk of needle-stick injury Facilitates unassisted technique LAUNCH DATE JULY 2012 Innovatio
Slide 53: WECK Vista Bladeless Laparoscopic Access Ports
Key New Product & Line Extension Launches WECK Vista(tm) Bladeless Laparoscopic Access Ports PRODUCT DESCRIPTION Comprehensive offering of bladeless laparoscopic access ports featuring: Patented asymmetrical dilating tip Best in class optical entry Stability ridges for minimal tissue trauma Cost eff
Slide 54: Summary
Summary 54
Slide 55: Surgical Strategy
Surgical Strategy Surgical Strategy Selective market investment Revenue growth from higher-margin products Compress Development Cycle Enhance Opportunity/Technology Assessment Robust R&D Pipeline Customer Advocacy Innovative 55
Slide 56: Thank you for your attention
Thank you for your attention 56
Slide 57: Cary Vance, Anesthesia and Respiratory Division
Teleflex Incorporated - 2012 Analyst Day Cary Vance President - Anesthesia and Respiratory Division December 13, 2012 57
Slide 58: Key Takeaways
58 Key Takeaways Market Overview Strategic Priorities Acquisition Update Research and Development Pipeline Summary 58
Slide 59: Market Overview
Market Overview 59
Slide 60: Global Anesthesia and Respiratory Position by Product Group
Global Anesthesia and Respiratory Position by Product Group Dollars in Millions Global Position by Product Group 2011 Market CAGR $1,700 2.4% $1,250 3.1% $624 5.0% 14% 9% 10% Market data and Teleflex percentages based on management estimates. Actual amounts could differ. 60
Slide 61: Global Anesthesia and Respiratory Market
Global Anesthesia and Respiratory Market CAGR 6.3% 2.0% 3.2% $3.6B $3.9B $4.1B $3.8B $4.3B * Includes Latin America Market data and Teleflex percentages based on management estimates. Actual amounts could differ. 61
Slide 62: Global Market Segments and Trends
Global Market Segments and Trends Market data and Teleflex percentages based on management estimates. Actual amounts could differ. 62
Slide 63: Strategic Priorities
Strategic Priorities 63
Slide 64: Strategic Priorities
Leadership products Differentiated products with sustainable advantage through outcome driven innovation Continued investment in clinical research and education to support value proposition, drive best- practices, accelerate market adoption Product mix Introduction of higher margin respiratory thera
Slide 65: Acquisition Update
Acquisition Update 65
Slide 66: EZ-Blocker
EZ-BlockerTM Acquired single-use catheter product line during 2nd quarter of 2012 Patented bronchial blocker for lung isolation and one-lung ventilation Addition to Rusch(r) Airway portfolio Unique bifurcated distal end CE Mark approval obtained in Europe 510(k) approval September 2012 66
Slide 67: Research and Development Pipeline
Research and Development Pipeline 67
Slide 68: 2012 - 2013 New Product & Line Extensions
2012 - 2013 New Product & Line Extensions 2012 Softech Plus Nasal Cannula 2013 Arrow FlexTip Plus Multi-Port Epidural Catheter ISO-Gard Circuit Technology Rusch Nylon Epidural Catheter ISO-Gard Mask with ClearAir Technology Comfort Flo High Flow Oxygen System ConchaTherm Neptune Heated Humidifier Ar
Slide 69: ARROW FlexTip Plus Multi-Port Epidural Catheter
Key New Product & Line Extension Launches ARROW FlexTip Plus(r) Multi-Port Epidural Catheter PRODUCT DESCRIPTION Closed tip, multi-port design epidural catheter Designed from the proven technology of the open tip FlexTip Plus, which is clinically proven to significantly reduce complications in the e
Slide 70: ARROW FlexBlock Continuous Peripheral Nerve Block Catheter
Key New Product & Line Extension Launches ARROW FlexBlock(tm) Continuous Peripheral Nerve Block (cPNB) Catheter PRODUCT DESCRIPTION Intended for clinicians who use ultrasound-guidance when placing continuous peripheral nerve block catheters Echogenic, coil-reinforced FlexBlock Catheter body is const
Slide 71: ARROW UltraQuik Single-Shot Peripheral Nerve Block Needle
Key New Product & Line Extension Launches ARROW UltraQuik(tm) Single-Shot Peripheral Nerve Block Needle PRODUCT DESCRIPTION Non-stimulating single-shot Peripheral Nerve Block Needle with echogenic characteristics Five etched rings at the distal end of the needle cannula to help clinicians identify t
Slide 72: RUSCH Nylon Epidural Catheter
Key New Product & Line Extension Launches RUSCH Nylon Epidural Catheter PRODUCT DESCRIPTION Low-cost nylon epidural catheter Price point will allow for expansion of Teleflex market share in Europe, Asia and Latin America markets LAUNCH DATE Full Market Release Q3 2013 72
Slide 73: ISO-Gard Circuit Technology
Key New Product & Line Extension Launches ISO-Gard(r) Circuit Technology PRODUCT DESCRIPTION Promotes a closed system ventilation approach by integrating reservoirs into the breathing circuit that collect excess condensate or secretions, which can be easily emptied with a suction wand Helps to reduc
Slide 74: ISO-Gard Mask with ClearAir Technology
Key New Product & Line Extension Launches ISO-Gard(r) Mask with ClearAir(tm) Technology PRODUCT DESCRIPTION Multi-purpose product that: Reduces hazardous WAG within breathing zone of caregiver Minimizes the cumulative effect of low level exposure of WAG to caregiver Provides unidirectional flow of o
Slide 75: ConchaTherm Neptune Platform Project
Key New Product & Line Extension Launches ConchaTherm Neptune Platform Project PRODUCT DESCRIPTION LAUNCH DATE 1.Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29:S31-S40. Full Market Release
Slide 76: Comfort Flo High Flow Oxygen Therapy System
Key New Product & Line Extension Launches Comfort Flo(r) High Flow Oxygen Therapy System PRODUCT DESCRIPTION LAUNCH DATE 1.Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29:S31-S40. Full Marke
Slide 77: Summary
Summary 77
Slide 78: Summary
Summary Become a world-class critical care solutions provider Drive customer advocacy Improve patient outcomes and reduce the cost of care to the hospital 78
Slide 79: Thank you for your attention
Thank you for your attention 79
Slide 80: Liam Kelly, International Division
Teleflex Incorporated - 2012 Analyst Day Liam Kelly Executive Vice President & President - International Division December 13, 2012 80
Slide 81: Key Takeaways
81 Key Takeaways Market Overview Strategic Priorities Acquisition Update Research and Development Pipeline Summary 81
Slide 82: Market Overview
Market Overview 82
Slide 83: International - Market Overview
Source: Notes: Developed nations defined as having GPD per capita greater than $X Sources - WorldBank , UNFPA.ORG ~ 7 billion inhabitants ~ 85% are in APAC/EMEA regions International spans 17 Direct Operations ~ 400 people in Sales and Marketing Manufacturing in Malaysia, Germany, Czech and India ~
Slide 84: Strategic Priorities
Strategic Priorities 84
Slide 85: Strategic Priorities
Accelerate growth in Asia Pacific Accelerate new product introductions Invest in China, India and Southeast Asia Execute go-direct strategy in Japan Continue to take price Expand gross and operating margins in EMEA Remove lower margin 3rd party products Distribution and manufacturing footprint conso
Slide 86: Acquisition Update
Acquisition Update 86
Slide 87: Global Laryngeal Mask Market
Global Laryngeal Mask Market CAGR 4.0% 6.6% 7.2% $188M 87 Market data and Teleflex percentages based on management estimates. Actual amounts could differ.
Slide 88: LMA Strategic Priorities
LMA Strategic Priorities Expand Global leadership position in Airway Management Significant growth opportunities in Asia and Latin-America Nasal drug delivery in its infancy; atomization is positioned to take advantage; opportunity to exploit vaccination market Strong patent portfolio and network of
Slide 89: Research and Development Pipeline
Research and Development Pipeline 89
Slide 90: 2012 - 2013 New Product & Line Extensions
2012 - 2013 New Product & Line Extensions 2012 Hotspur GPS Cath 2013 EZ Blocker Trans-Radial CE Mark PICC & VPS CE Mark Chronic Hemodialysis Ready-to-Use Jelly Intermittent TrachFlex Plus MRI-Suction LMA Unique EVO Pre-activated Intermittent LMA Protector Ready-to-Use Intermittent Next-Gen Cuff & CP
Slide 91: Ready-to-Use Intermittent Catheters
Key New Product & Line Extension Launches Ready-to-Use Intermittent Catheters PRODUCT DESCRIPTION New discrete packaging Integrated ergonomic handling features Higher reimbursement in select markets Creates platform for Pre-Activated LAUNCH DATE Planned launch in March 2013 - Female-specific, Jelly
Slide 92: LMA Protector
Key New Product & Line Extension Launches LMA Protector PRODUCT DESCRIPTION 3rd Generation LMA technology Multiple Patented design features Clinically proven enhanced sealing during regurgitation LAUNCH DATE Expected launch Q1 2014 92
Slide 93: TrachFlex Plus MRI with Suction
Key New Product & Line Extension Launches TrachFlex Plus MRI with Suction PRODUCT DESCRIPTION World's first Tracheostomy combining reinforced cannula and MRI compatibility with Subglottic suctioning capability. LAUNCH DATE Availability planned in September 2013 93
Slide 94: Summary
Summary 94
Slide 95: Summary
Summary Accelerate growth in Asia Pacific markets Expand gross and operating margins in EMEA Successfully integrate LMA acquisition 95
Slide 96: Thank you for your attention
Thank you for your attention 96
Slide 97: Thomas Powell, Senior Vice President and CFO
Teleflex Incorporated - 2012 Analyst Day Thomas Powell Senior Vice President and Chief Financial Officer December 13, 2012 97
Slide 98: Key Takeaways
98 Key Takeaways Long-term Growth and Profitability Objectives 2013 Preliminary Financial Outlook Summary Historical Financial Review 98
Slide 99: Long-term Growth and Profitability Objectives
Long-term Growth and Profitability Objectives 99
Slide 100: Long-term Growth and Profitability Objectives
Constant currency revenue growth of > 5% Gross margins of approximately 55% Research and development expense of approximately 5% Return on equity of approximately 15% Operating margins of approximately 25% Long-term Growth and Profitability Objectives Some progress achieved...significant opportunity
Slide 101: Historical Financial Review
Historical Financial Review 101
Slide 102: Financial Review - Revenue
Financial Review - Revenue Dollars in Millions 2008 2009 2010 2011 Sep-2012 YTD Medical 1499.1 1457.1 1433.3 1528.9 1131.953 Non-Medical 921.8 433 368.4 0 0 Medical Constant Currency Revenue Growth % 0.02 0 0.01 0.043 0.074 Note: amounts per Form 10K / 10Q during year filed. 102
Slide 103: Financial Review - Gross Margin
Financial Review - Gross Margin Note: amounts per Form 10K / 10Q during year filed. 103 2008 2009 2010 2011 Sep-2012 YTD Gross Margin 0.398 0.431 0.441 0.47 0.485
Slide 104: Financial Review - Research and Development
Financial Review - Research and Development Dollars in Millions 2010 2011 Sep-2012 YTD Research and Development Expense 42.6 48.7 40.015 Percentage of Revenue 0.024 0.032 0.035 Note: amounts per Form 10K / 10Q during year filed. Company did not separately disclose research and development spending a
Slide 105: Financial Review - Adjusted Operating Margin
Financial Review - Adjusted Operating Margin Note: see Appendix for reconciliation of GAAP to adjusted results. 105 2008 2009 2010 2011 Sep-2012 YTD Adjusted Operating Margin 0.158 0.157 0.158 0.162 0.165
Slide 106: 2013 Preliminary Financial Outlook
2013 Preliminary Financial Outlook 106
Slide 107: 2013 Preliminary Financial Outlook - Highlights
2013 Preliminary Financial Outlook - Highlights Including full year impact of LMA acquisition, constant currency revenue growth expected to be between 11% to 13% Gross margin of between 50% to 51% Including impact of medical device tax, adjusted operating margin expected to be between 16.0% to 17.0%
Slide 108: 2013 Preliminary Financial Outlook - Revenue
2013 Preliminary Financial Outlook - Revenue Foreign exchange expected to negatively impact revenue by ~ 1% 108
Slide 109: 2013 Preliminary Financial Outlook - Adjusted Earnings per Share
2013 Preliminary Financial Outlook - Adjusted Earnings per Share Adjusted earnings per share growth of between 7% to 13% 109
Slide 110: 2013 Preliminary Financial Outlook - Assumptions
2013 Preliminary Financial Outlook - Assumptions Euro to U.S. Dollar exchange rate assumed to be ~ 1.26 Medical device tax of 2.3% in-effect for all of 2013 2 less selling days in Q1'13 vs. Q1'12; 1 additional selling day each in Q2'13 and Q4'13 vs. Q2'12 and Q4'12 Weighted average shares assumed to
Slide 111: Summary
Summary 111
Slide 112: 2013 Preliminary Financial Outlook - Summary
2013 Preliminary Financial Outlook - Summary Continue to expect strong constant currency revenue growth fueled by a combination of pricing initiatives, new product introductions, and contributions from recently closed acquisitions Pricing, mix, cost improvements, and LMA acquisition, lead to gross m
Slide 113: Thank you for your attention
Thank you for your attention 113
Slide 114: Q&A
Q&A 114
Slide 115: Benson Smith, Chairman, President and CEO
Teleflex Incorporated - 2012 Analyst Day Benson Smith Chairman, President and Chief Executive Officer December 13, 2012 115
Slide 116: Why Will Teleflex Win?
Why Will Teleflex Win? Opportunity to generate above-market revenue growth rates Not dependent upon any one product or geography Not overly impacted by elective procedure downturns Established, global distribution network Near-term pricing opportunities Mix of future new products Ability to improve
Slide 117: Thank you for your attention
117 Thank you for your attention
Slide 118: Appendices
Appendices Teleflex: 1
Slide 119: Operating Profit and Margin Reconciliation
Operating Profit and Margin Reconciliation Dollars in Millions Note: GAAP results represent amounts per Form 10K / 10Q during year filed. 119
Slide 120: Free Cash Flow Reconciliation
Free Cash Flow Reconciliation Dollars in Millions Note: GAAP results represent amounts per Form 10K / 10Q during year filed. 120
Slide 121: 2013 Earnings per Share Reconciliation
2013 Earnings per Share Reconciliation 121 Low High Diluted earnings per share attributable to common shareholders $3.28 $3.48 Restructuring and impairment charges, net of tax $0.43 $0.43 Intangible amortization expense, net of tax $0.82 $0.82 Amortization of debt discount on convertible notes, net
Slide 122: September 2012 Year-to-Date: Medical Constant Currency Revenue Growth Reconciliation
September 2012 Year-to-Date: Medical Constant Currency Revenue Growth % Reconciliation 122 Note: amounts per Form 10Q during year filed.
Slide 123: 2011: Medical Constant Currency Revenue Growth Reconciliation
2011: Medical Constant Currency Revenue Growth % Reconciliation 123 Note: amounts per Form 10K during year filed.
Slide 124: 2010: Medical Constant Currency Revenue Growth Reconciliation
2010: Medical Constant Currency Revenue Growth % Reconciliation 124 Note: amounts per Form 10K during year filed.
Slide 125: 2009: Medical Constant Currency Revenue Growth Reconciliation
2009: Medical Constant Currency Revenue Growth % Reconciliation 125 Note: amounts per Form 10K during year filed.
Slide 126: 2008: Medical Constant Currency Revenue Growth Reconciliation
2008: Medical Constant Currency Revenue Growth % Reconciliation 126 Note: amounts per Form 10K during year filed.